A Non-randomized, Open-label, Prospective, Multicenter Study of Apatinib Mesylate Tablet as Second-line and Later Therapy in Patients With Extensive Stage Small Cell Lung Cancer

Trial Profile

A Non-randomized, Open-label, Prospective, Multicenter Study of Apatinib Mesylate Tablet as Second-line and Later Therapy in Patients With Extensive Stage Small Cell Lung Cancer

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top